Drugs / Stempeucel(R)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03056742 | Feb 2017 → Apr 2018 | thromboangiitis obliterans | Stempeutics Research Pvt Ltd | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-08-17 | Stempeutics Research Pvt Ltd | Regulatory Alkem and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia stempeutics.com ↗
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. |
| 2015-06-01 | Stempeutics Research Pvt Ltd | Regulatory Stempeutics receives Orphan Drug Designation (ODD) in the European Union for its novel stem cell drug “Stempeucel®” for the treatment of Thromboangiitis Obliterans stempeutics.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stempeucel(R) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03056742 ↗ |
| Known as | Stempeucel | “A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease” NCT03056742 ↗ |
| Modality | Cell therapy | “Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells” NCT03056742 ↗ |
| Route | Intramuscular | “intramuscular injection of stempeucel(R)” NCT03056742 ↗ |